

Curriculum Vitae
David Paul Speert, M.D.

RECEIVED
TECH CENTER 1600/2900
02 SEP 23 AM 11:16

Birthdate: September 30, 1947
 Birthplace: New York, New York
 Citizenship: U.S.A.; Canada
 Marital Status: Married - June 11, 1977
 Spouse - Sarah Lawton-Speert
 Children - Rachel Lawton Speert, Born Feb 10, 1982
 Nathaniel Lawton Speert, Born Dec 16, 1986
 Zachary Lawton Speert, Born Sept 3, 1988

Address: BC Research Institute for Children's and Women's Health
 377 - 950 West 28th Ave., Vancouver, B.C., Canada , V5Z 4H4

Education:

1961-1965 Edgemont High School, Scarsdale, New York
 1965-1969 B.A. - Middlebury College, Middlebury, Vermont
 1969-1973 M.D. - Columbia University, College of Physicians and Surgeons, New York, New York

Graduate Training:

1973-1974 Internship, Pediatrics, University of Michigan
 1974-1976 Residency, Pediatrics, University of Michigan
 1976-1977 Chief Resident, Department of Pediatrics, University of Michigan
 1977-1980 Medical Fellow, Dept. of Pediatrics, Div. of Infectious Diseases, University of Minnesota

Professional Appointments:

1998- Associate Director, Centre for Microbial Diseases Research, UBC
 1996-2000 Associate Member, Dept. of Pathology & Lab. Medicine, University of B.C.
 1993-1995 Assistant Director, Research Division, British Columbia's Children's's Hospital
 1992- Assistant Head (Research) Department of Pediatrics, University of B.C.
 1991- Head, Division of Infectious and Immunological Diseases, Department of Pediatrics
 1990- Professor, Department of Pediatrics, University of British Columbia
 1985-1990 Associate Professor, Department of Pediatrics, University of British Columbia
 1982- Associate Member, Department of Microbiology, University of British Columbia
 1980-1985 Assistant Professor, Department of Pediatrics, University of British Columbia
 1976-1977 Instructor, Department of Pediatrics, University of Michigan

Boards and Consultancies:

1989-94 *Antimicrobial Agents and Chemotherapy*, Editorial Board
 1993- Micrologix Inc., Scientific and Medical Advisory Board

Sept. 18, 2002

EXHIBIT "A" (continued)

1994-2001	<i>The Pediatric Infectious Disease Journal</i> , Editorial Board
1994-97	Vancouver Association for Learning Disabilities, Board of Directors
1999-2000	Vancouver Peretz Institute – Board of Directors
1999	Executive Committee – Canadian CF Foundation
2000	BCY LifeSciences – Clinical Advisory Board
2000	Associate Chair – BC Lung Association Medical Advisory Committee
2001	The American Journal of Respiratory Medicine, Editorial Board

Grants Committees:

1993-1996	Medical Research Council of Canada - Microbiology and Infectious Diseases Committee
1987-1988	Scholarship & Fellowship Subcommittee member - B.C. Health Care Research Foundation
1998-1999	Canadian Cystic Fibrosis, Scientific Advisory Committee

Ad hoc Reviewer

Journals:

Infection and Immunity
Journal of Infectious Diseases
Pediatric Research
Journal of Pediatrics
European Journal of Clinical Microbiology and Infectious Diseases
Clinical and Experimental Immunology
Biochimica et Biophysica Acta
Canadian Journal of Microbiology
FEMS Microbiology Letters
American Review of Respiratory Diseases
Reviews of Infectious Diseases
Journal of Clinical Investigation
Clinical and Investigative Medicine
Pediatric Infectious Diseases
Microbial Pathogenesis
Journal of Clinical Microbiology
Canadian Journal of Pediatrics
Journal of Leukocyte Biology
Thorax
Journal of Cell Science

Granting Agencies:

Canadian Cystic Fibrosis Foundation
Medical Research Council (Canada)
Science Council of British Columbia
Western Provinces Lung Association
Natural Sciences and Engineering Research Council (Canada)
Veterans Administration (USA)
National Health Research and Development Program (Canada)

B.C. Health Care Research Foundation
Association Française de Lutte Contre Mucoviscidose
Cystic Fibrosis Trust
Alberta Heritage Foundation
Australian Cystic Fibrosis Trust
Cystic Fibrosis Foundation (US)
Wellcome Trust

External Review Board:

Colorado Cystic Fibrosis Research and Development Program (USA)

Site Reviews:

Univ. of Calgary Research Development Programme for Lung Infections in Cystic Fibrosis, Feb. 1991
Univ. of Washington, CF Foundation Research Dev. Project & NIH Research Center, July 1991
Univ. of Manitoba, MRC Group, April 1998

Fellowships, Awards and Certifications:

1977-1980	U.S. Public Health Service Traineeship (NIAID)
1977	Diplomate, National Board of Medical Examiners (USA)
1978	Diplomate, American Board of Pediatrics
1981	Fellow, Royal College of Physicians and Surgeons (Canada), Pediatrics
1987-1992	Scholar, Canadian Cystic Fibrosis Foundation
1988	Fellow, Pediatric Infectious Diseases Society
1989	Detweiler Travel Fellowship, MRC of Canada
1991	Fellow, Infectious Diseases Society of America
1993	Royal College of Physicians and Surgeons of Canada lecturer (Banff Conference)
1994	Outstanding Achievement by Investigator, BC Research Institute for Child & Family Health

Society Membership:

American Society for Microbiology
Canadian Paediatric Society
Western Society for Pediatric Research
Infectious Diseases Society of America
Society for Pediatric Research
American Pediatric Society
Pediatric Infectious Diseases Society

Committees, Local and National Responsibilities:

1982-1993	Hamber Library Committee - BC's Children's Hospital (Chairman)
1984-1989	Mortality Review Committee - BC's Children Hospital
1985-1994	Antibiotic Utilization Committee - BC's Children's Hospital (Chairman)
1987-1988	Department of Pediatrics Fundraising Committee (Chairman)
1987-	Infection Control Committee - BC's Children's Hospital

EXHIBIT "A" (continued)

1987-	Dept. of Pediatrics Standing Committee on Appointments, Reappointments, Promotion & Tenure
1988-1993	Advisory Committee, Vaccine Evaluation Centre
1989-1992	Working Group on Infection Control in Out-of-Home Child Care, Canadian Pediatric Society (Co-chairman)
1990-1991	Department of Pediatrics, Finance Committee (Chairman)
1990-1992	Director, Pediatric Infectious Diseases Fellowship Training programme
1991-	Steering Committee on Pediatric Clinical Trials, Canadian Infectious Diseases Society
1992-1993	Consultant, Canadian Cystic Fibrosis Foundation Clinic Subcommittee
1992-1995	Scientific Review Committee, Institute for Child and Family Health, BC's Children's Hospital (Chairman)
1993	Chair, Div. of Infectious Diseases, Dept. of Medicine (UBC) Review Committee
1993-1996	Abbott Laboratories, Pediatric Advisory Board
1993-1998	Medical Advisory Committee, BC's Children's Hospital
1993-1999	Canadian Pediatric Society, Infectious Diseases and Immunization Committee
1994-1995	Headship Search Committee, Div. of Pediatric Cardiology (Chair)
1994-	Research Coordinating Committee, UBC
1994-	Headship Search Committee, Div. of Pediatric Respiriology (Chair)
1995	Headship Search Committee, Div. of Infectious Diseases, Dept. of Medicine, UBC
1995-	Chairman, Canadian Cystic Fibrosis Foundation, Clinical Studies Network
1995-	Space Planning Committee, BC Research Institute for Children's and Women's Health
1996-1997	Headship Search Committee, Department of Microbiology, University of BC
1996	Chair, Div. of Emergency Medicine, Dept. of Pediatrics (UBC) Review Committee
1996-	Co-chair, International <i>Burkholderia cepacia</i> Working Group
1997	Steering Committee, Canadian Consensus Conference on Antimicrobial Resistance
1998	Headship Search Committee, Department of Pharmacology & Therapeutics, UBC
1998	Chair, Antibiotic Advisory Committee - Zeneca Pharma, Inc.
1998-1999	Academic Plan Advisory Committee, UBC
1998-	Coordinator, Canadian Bacterial Diseases Network, Vancouver Node
1998-	Research Subcommittee, CCFF Medical/Scientific Advisory Committee
1998-	Emerging Infections Committee, Infectious Diseases Society of America
1999	Review Committee, Div. of Critical Care, Dept. of Pediatrics, UBC
1999-	Search Committee, Developmental Pediatrics, UBC
1999-	Ped. Infect. Dis. Soc. Training Programs Committee
1999-	Canadian Cystic Foundation Medical Scientific Advisory Executive Committee
2000-2001	Chair, Canadian Foundation for Innovation (CFI)
2000-2001	Committee Member, Wet Lab Space Committee
2000-	Chair, Career Awards Task Force (CASC)
2001-	Investigator and Administrator, Laboratory Investigator's Network (LIN)
2001-	BC Research Institute of Children's and Women's Health (BCRICWH), Selection Advisory Scientific Member
2001-	Training Program in Infection and Immunity
1999-2002	MD/PhD Committee Member
2001-	Committee Member, Emergency Search Committee
2000-2001	Committee Member, Faculty Appointments, Reappointments, Promotions and Tenure (FARPT)
2001	Academic Enhancement Fund
2001	Council of University Teaching Hospital, (COUTH)

Miscellaneous Activities:

EXHIBIT "A" (continued)

- 1970 (Summer) - Research in High Altitude Pulmonary Edema with Dr. Herbert Hultgren, Stanford University, Palo Alto, California.
- 1972 (Sept-Oct) - Medicine in The Tropics Elective. Katete, Zambia.
- 1980 (Feb-Apr) - Volunteer physician in the Nong Khai Refugee Camp, Nong Khai, Thailand.
- 1981 (March 2-5) - Attended an Indo-U.S. Conference-Workshop in New Delhi, India entitled "Rheumatic Fever in the 1980's".
- 1984 (June 7-8) - Organized an international symposium entitled, "*Pseudomonas aeruginosa*: new therapeutic approaches from basic research", in Vancouver, B.C. Also edited a book containing the proceedings.
- 1984 (Sept-Dec) - Research in the laboratory of Dr. Samuel Silverstein, Department of Physiology, Columbia University, N.Y. Studied macrophage function and receptor physiology.
- 1987 (April) - Organized a conference entitled "Macrophage function in host defense" at Whistler, B.C.
- 1989 - 1990 - Sabbatical in the laboratory of Dr. Siamon Gordon, Sir William Dunn School of Pathology, University of Oxford.
- 1990 - Member, Canadian Bacterial Diseases Network, Networks of Centres of Excellence. Chairman Working Group. "Adherence, Entry and Intracellular Survival"
- 1991 (July) - Convened and chaired a workshop on *Pseudomonas cepacia* infections in patients with cystic fibrosis sponsored by the Canadian Cystic Fibrosis Foundation, Toronto, Ont.
- 1992 (Feb) - Convened and chaired international conference on Pediatric Infectious Diseases at Child Health 2000, Vancouver, B.C.
- 1996 (June) - Convened and co-chaired 1st International Workshop on *Burkholderia cepacia*. Bethesda, MD
- 1996 (Oct) - Convened and co-chaired 2nd International Workshop on *Burkholderia cepacia*. Orlando, FL
- 1997 (May) - Convened and co-chaired 3rd International Workshop on *Burkholderia cepacia*. Victoria, BC
- 1997 (Oct) - Co-chaired 4th International Workshop on *Burkholderia cepacia*, Nashville, TN
- 1998 (March) - Convened and co-chaired 5th International Workshop on *Burkholderia cepacia*, Miami, FL
- June 5, 2002 - Antimicrobial Resistance Meeting, Toronto, Ontario

Invited Presentations:

- Oct 1981 - Fourth Canadian Cystic Fibrosis Foundation Professional Conference. Banff, Alberta.
- Oct 1984 - Columbia University, New York. Department of Microbiology.
- Sep 1985 - Canadian Pediatric Society, Annual Meeting, Vancouver.
- Nov 1986 - University of Victoria, Victoria, B.C., Department of Microbiology and Biochemistry.
- Apr 1986 - Rockefeller University, New York, Laboratory of Cellular Physiology and Immunology.
- May 1986 - UA-UC Conference on Infectious Diseases, Invermere, B.C.
- Jun 1986 - Regional ASM Meeting, Vancouver, B.C.
- Apr 1987 - Symposium, "Macrophage function in host defense". Whistler, B.C.
- Jul 1987 - Gordon Conference on Molecular Mechanisms of Microbial Adhesion.
- Sep 1987 - University of Chicago - Infectious Diseases Research Seminar.
- Oct 1987 - Michael Reese Hospital, Chicago. Department of Pediatrics Grand Rounds.
- Oct 1987 - Columbia University, Department of Physiology.
- Sep 1988 - Canadian Infectious Diseases Society, Montebello, Quebec.
- Nov 1988 - Dept of Pediatrics, Memorial University, St. John's, Newfoundland.
- Nov 1988 - Dept of Pediatrics, Dalhousie University, Halifax, Nova Scotia.
- Nov 1988 - Dept of Pediatrics, John Radcliffe Hospital, University of Oxford, UK
- May 1989 - Dept of Medicine, Harbor - UCLA Medical Center

EXHIBIT "A" (continued)

- Jun 1989 - International Workshop for Pseudomonas Vaccine Development. Kananaskis, Alberta.
- Jan 1990 - Central Public Health Service Laboratory, Colindale, London, UK.
- May 1990 - Dept of Pediatrics, John Radcliffe Hospital, University of Oxford, UK.
- May 1990 - John Squire lecture, The University of Birmingham, UK.
- May 1990 - Dept of Clinical Microbiology, John Radcliffe Hospital, Oxford, UK.
- Jun 1990 - Dept of Microbiology, Hygiene Institute, University of Tubingen, Germany
- Mar 1991 - North Pacific Pediatric Society, Vancouver, B.C.
- May 1991 - Annual Meeting, American Society for Microbiology Symposium on "Molecular Mechanisms of Nonopsonic Phagocytosis of Bacteria".
- May 1991 - Division of Infectious Diseases, Department of Pediatrics, University of Minnesota.
- Oct 1991 - Fifth North American Cystic Fibrosis Conference, Dallas, Texas. "Epidemiologic studies in cystic fibrosis"
- Nov 1991 - 22nd Annual Western Branch Meeting - Canadian Society of Microbiologists.
- Nov 1991 - Hospital for Sick Children - Toronto, Division of Infectious Diseases
- Dec 1991 - University of Calgary Immunology Research Seminar Program
- Feb 1992 - Child Health 2000, Vancouver, B.C. "Tuberculosis: New thoughts on epidemiology and therapy"
- Sep 1992 - Heinz Seminar, Canadian Pediatric Society, Ottawa, Ontario. "Gastrointestinal infections"
- Oct 1992 - North American Cystic Fibrosis Conference, Washington, D.C. "Regulation of nonopsonic phagocytosis of *P. aeruginosa*"
- Nov 1992 - Department of Cell Analysis, Genentech, So. San Francisco, CA. "Lung infections in cystic fibrosis: new observations on an old problem"
- Feb 1993 - Second Annual Pediatric Infectious Diseases Conference, Banff, Alberta. "Management of common infections in your office" and "Immunomodulation therapy in pediatrics"
- Mar 1993 - French Cystic Fibrosis Foundation Symposium, Fillerval, France. "Comparison of different typing methods"
- Apr 1993 - Hospital Infantil de Mexico, Mexico City. "Interactions between Pseudomonas and phagocytic cells: the critical influences of bacterial and host factors"
- Jun 1993 - Eighth Broken Arrow Conference, Canadian Cystic Fibrosis Foundation. Mont Ste-Anne, Quebec. "Antibacterial Host Defenses"
- Jul 1993 - Fourth International Symposium on Pseudomonas. Vancouver, B.C. "Interaction of *Pseudomonas aeruginosa* with macrophages"
- Sep 1993 - Intracellular Pathogens Old and New. Campbell River, B.C. "Phagocytic defenses in mycobacterial infections"
- Oct 1993 - North American Cystic Fibrosis Foundation Annual Meeting, Dallas, TX. Canadian CF Clinic Directors, "Pseudomonas repository: an update"
- Mar 1994 - University of Manitoba, Department of Pediatrics, Grand Rounds. "Lung Infections in patients with cystic fibrosis: new observations on an old problem" Department of Pediatrics, Research Rounds. Macrophage-*Pseudomonas aeruginosa* interactions in the cystic fibrosis lung: phagocyte-bacterial détente.
- May 1994 - 4th Annual David Hines Memorial Lecture, Pediatric Clinical Microbiology Society, Las Vegas. "Lung infections in cystic fibrosis: new observations on an old problem"
- May 1994 - American Society for Microbiology, Annual Meeting, Las Vegas. "Clinical spectrum and bacterial variation during chronic mucosal colonization by *Pseudomonas aeruginosa*"
- May 1994 - UA-UC International Conference on Infectious Diseases, Kananaskis, Alberta. "Modulation of phagocytic defenses against *Pseudomonas aeruginosa*: role of facilitative glucose transport in host defense of the lung"
- Jun 1994 - 19th European Cystic Fibrosis Conference, Paris. "Summary of AFLM consensus conference"

EXHIBIT "A" (continued)

- Jun 1994 - 44th Annual Canadian Society for Microbiology Meeting, Vancouver. "Phagocytic defenses against infection with *Mycobacterium tuberculosis*"
- Jun 1994 - Canadian Society for Laboratory Technologists, Vancouver. "Cystic fibrosis lung infections and *Pseudomonas* research"
- Sep 1994 - Macrophages in Health and Disease: An International Symposium, Oxford, UK. "The role of facilitative glucose transport in receptor-mediated phagocytosis by macrophages"
- Jan 1995 - Dept. of Surgery, University of Toronto, and Div. of Cell Biology, Hospital for Sick Children, Toronto.
 - "Regulation of macrophage phagocytosis by glucose"
 - "Lung infections in cystic fibrosis: new observations"
- Mar 1995 - 4th Annual Pediatric Infectious Diseases Course, Banff, Alberta.
 - "Antimicrobial resistance: practical implications for Pediatric Therapy"
 - "Tuberculosis: new solutions to an ancient problem"
- Jun 1995 - Dept. of Medical Microbiology and Infectious Dis., Univ. of Alberta. "Lung infections in cystic fibrosis: New observations on an old problem"
- Jun 1995 - Canadian Cystic Fibrosis Foundation - SPARx Workshop, Toronto, ON. "New approaches to lung infection - macrophages"
- Sep 1995 - Canadian Paediatric Society, CME Course #8, Whitehorse, Yukon:
 - "Tuberculosis"
 - "New antibiotics"
 - "Antibiotic resistance"
- Jan 1996 - Transatlantic Airway Conf., Lucerne, Switzerland - invited discussant
- Feb 1996 - Canadian Paediatric Society CME #9 Speaker Lectures, Vancouver, BC:
 - "New Antibiotics: Which? When? Why?"
 - "Antibiotic Resistance: Plague of the '90s?"
 - "Group A Strep: Much ado about nothing?"
- Apr 1996 - Univ. of Washington and Children's Hospital Grand Rounds: "Lung infections in cystic fibrosis: New approaches to an old problem"
- Apr 1996 - 5th National Adult CF Conference, Vancouver, BC. "The private life of *Burkholderia cepacia*"
- May 1996 - Max von Pettenkofer-Institut, Munich. "Lung infections in CF: New strategies for prevention"
- May 1996 - 2nd Intl. Mtg. New Approaches to Bacterial Vaccine Development, Munich. "Modulation of macrophage function for defense of the lung against infection with *P. aeruginosa*"
- Jul 1996 - Tuberculosis control for low prevalence countries. "Pediatric Tuberculosis," Vancouver
- Aug 1996 - Intl. Union of Microbiological Societies Congresses '96, Jerusalem. "Resistance of *Pseudomonas aeruginosa* to macrophage phagocytosis: A possible mechanism for evasion of host defences in the lung"
- Oct 1996 - Cowichan District Hospital: "Antibiotic resistance: Problems and solutions for the practising physician"
- Nov 1996 - "Issues in Cystic Fibrosis Antibiotic Therapy", Royal College of Pathologists, London, UK: "Lessons learned in North American clinics"
- Mar 1997 - Cystic Fibrosis - *Burkholderia cepacia* in Lung Transplantation Conf., Toronto, ON: "Genetic typing and virulence of strains of cepacia"
- Mar 1997 - Strategic Planning on Antibiotic Resistance in Ontario (SPARO), Toronto, ON: "Control programs: The role of health promotion (with Ms. D. Katzenstein)"
- Apr 1997 - UBC Dept. of Pediatrics 45th Reunion, Vancouver, BC: "How the bugs have changed"
- May 1997 - Management of Serious Infectious Diseases in the Third Millennium, Victoria, BC:
 - "Regional Report on Bacterial Resistance - BC"
 - "Antibiotic Control in the Community" - moderator

HIBIT "A" (continued)

- Jun 1997 - Keynote Speaker, Dept. of Pediatrics 5th Annual Research Day, Vancouver, BC: "The role of serendipity in scientific inquiry: blindly stumbling toward the holy grail"
- Aug 1997 - Inhaled Antibiotics Pre-Consensus Meeting - group discussion, Seattle, WA
- Sep 1997 - Immunology Research Group Emerald Lake Conf., Univ. of Calgary, AB - Sepsis-mediated cellular activation: "In defence of the lung: The role of macrophages in host defence against *P. aeruginosa*"
- Oct 1997 - 11th Annual NA Cystic Fibrosis Conference, Nashville, TN: "Why is *Burkholderia cepacia* so nasty? New insights into virulence determinants"
- Mar 1998 - Broken Arrow Conference, Mississauga, ON: Chair "Host Defences and Inflammation"; lecture: "Improving phagocytosis"
- May 1998 - 1998 CBDN/CMCI AGM, Banff, AB: "Unconventional strategies to prevent or treat bacterial lung infections"
- Jun 1998 - 48th Annual mtg. of Canadian Society of Microbiologists, Guelph, ON: "*Pseudomonas aeruginosa* in the cystic fibrosis lung: famine not feast"
- Jun 1998 - 6th Annual Western Conf. in Infectious Diseases, Blaine, WA: "Strategies for control of antibiotic prescribing in pediatrics"
- Sep 1998 - NPPS 157th Scientific Program, Victoria, BC: "Protecting your patients from developing antibiotic resistance"
- Oct 1998 - 12th Ann. N. Am. CF Conf., Montreal, QC, Symposium #20: Treatment of Lung Infection: Past, Present & Future: Antibiotics - colonization blockers"
 - "Is there inter-patient spread of *Pseudomonas aeruginosa* among CF patients?"
 - Regulation of inflammation by epithelial cells (co-moderator)
 - Poster discussion "Host defenses in the airway" (co-moderator)
- Oct 1998 - Antibiotic Stewardship Program, Whistler, BC: UBC Dept. of Pediatrics Antibiotic Resistance Education Project
- Nov 1998 - 36th Ann. Mtg. Infectious Diseases Society of America, Denver, CO: Hydrophilic Nosocomial Pathogens, "*Burkholderia cepacia* - Epidemiology and markers for transmissibility"
- Jan 1999 - UBC Dept. of Pediatrics Grand Rounds, Vancouver: "Tuberculosis: Scientific and artistic representation" (with Dr. Richard Cavell)
- Mar 1999 - Basic & Clinical Research in Chronic *Pseudomonas aeruginosa* lung infection in Cystic Fibrosis and Diffuse Panbronchiolitis - East meets West, Copenhagen, Denmark: "Macrophages and *P. aeruginosa*"
- Mar 1999 - UBC CME, 10th Annual Drug Therapy Decision Making Course, Richmond, BC: "Pediatric URTI's hypoamoxicillinemia"
- May 1999 - 60th Anniv. Symposium, Dept. of Microbiology & Immunology, U. of Western Ontario, Challenges of Microbial and Immune Diseases in the Next Millennium, London, ON: "*Burkholderia cepacia*: The changing face of an emerging pathogen"
- Feb 2000 - Cystic Fibrosis Foundation - Consensus Conference "The Inflammatory Process in the CF Lung" - Invited discussion "Therapeutic Manipulation", Chantilly, VA
- Mar 2000 - North Pacific Pediatric Society 160th mtg., Vancouver, BC: "Historical and artistic aspects of tuberculosis"
- Apr 2000 - International *Burkholderia cepacia* Working Group Mtg, Bethesda, MD:
- Apr 2000 - Canadian Cystic Fibrosis Foundation Annual Meeting, Victoria, BC: Medical Conference Program, CF Research: Proud of our progress. Confident of the future
- May 2000 - Invited Speaker, Williamsburg Conference, CF Fdn., Williamsburg, VA:
 - "Impact of infection on early lung disease"
 - "Animal Models"
- May 2001 - Infectious Diseases Conference.
 - Invited Speaker, Kananaskis, Alberta
- May 30/2001 - Cystic Fibrosis Foundation Consensus Conference on Infection Control.
 - Invited Speaker, Bethesda, Maryland. "Molecular Epidemiology Techniques"

EXHIBIT "A" (continued)

- Discussion of Specific Pathogens. "*B. cepacia*, including role of genomovars"
- Resume Discussion of Specific Pathogens. "*P. aeruginosa*"
- Sept. 2001 - Canadian Cystic Fibrosis Foundation. Eleventh Broker Arrow Conference. Invited Speaker, Toronto, Ontario. "Anti-adherent therapy"
- Dec. 2001 - 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC Conference. Speaker, Chicago, Illinois. "Chronic Granulomatous Disease: The Narrow Spectrum of Superoxide-Mediated Killing"
- June. 2002 - 4th Annual UBC Respiratory Research Retreat. Invited Speaker, Semi-Ah-Moo. "Dextran; A Novel Therapy for Lung Infections in CF."

<i>Post-doctoral Fellows Supervised</i>	<i>Period</i>	<i>Current Position</i>
1. Fereshteh Eftekhari, PhD	1982-1985	Dept. of Biology, Behesati Univ., Tehran, Iran
2. David A. Cabral, MD	1984-1985	Clinical Instructor, Dept. of Pediatrics, UBC
3. Bonnie Cham, MD	1988-1989	Dept. of Peds., U. of Manitoba
4. Elizabeth Wilson, MD	1989-1989	Pediatrician, Auckland, New Zealand
5. Janet Kluftinger, PhD	1989-1990	
6. Richard Stokes, PhD	1990-1994	Assoc. Prof., Dept. of Pediatrics, UBC
7. Sameer Barghouthi, PhD	1991-1995	Asst. Prof., Al-Quds Univ., Al-Beireh, West Bank
8. E. Mahenthalingam, PhD	1991-1995	Lecturer, University of Cardiff, Wales
9. Mason Bond, MD	1991-1992	Dept. of Peds., Univ. of B.C.
10. Britt-Inger Marklund, PhD	1992-1995	Research Associate, Univ. of Umeå, Sweden
11. Karin Everett, PhD	1992-1994	USDA, National Animal Disease Ctr., Ames, Iowa
12. Simon Wong, PhD	1994-1997	Group Leader, Polysaccharide Vaccines, Jenner Inst., UK
13. Mary Macdonald, PhD	1994-1996	
14. Robert Sargeant, PhD	1995-1996	Medical Student, Univ. of Toronto
15. David Simpson, PhD	1995-2000	Scientist, Osel Inc., Palo Alto, Calif.
16. Ning Dan, MD, PhD	1997-1998	
17. Xiaowen Liao Bina, PhD	1997-1999	PDF, Molec. Biol. & Microbiol., Tufts Univ. (S. Levy)
18. Cheng-Hsun Chiu, MD, PhD	1997-1999	Attending Physician, Chang Gung Children's Hospital, Taoyuan, Taiwan
19. David Greenberg, MD	1998-1999	Asst. Prof., Peds., Soroka U. Medical Ctr., Israel
20. Leah Macfadyen	1999-1999	Asst. Coordinator, Western Regional Office, Médecins sans Frontières, Canada
21. J.-P. Heale, PhD	1998-	Research Associate, Dept. of Peds., UBC
22. Yoichi Hirakata, MD, PhD	1998-2000	Asst. Professor, Univ. of Nagasaki
23. Barbara-Ann Conway, PhD	2000-	Research Associate, Dept. of Peds., UBC
24. Andrew Pollard, MD, PhD	2000-2001	Clinical Instructor, Dept. of Peds., UBC
25. Donald Davidson, MB ChB PhD.	2000 -	Post Doctoral Fellow, UBC
26. Andrew Currie, PhD.	2001 -	Post Doctoral Fellow, UBC

External Examiner for PhD defence:

- | | |
|--------------------|------|
| 1. Shauna Doherty | 1995 |
| 2. Wai Keung Leung | 1998 |

EXHIBIT "A" (continued)

3. Jaime Bellatin 1999
4. Monisha Scott 2002

Graduate Students Supervised:

- | | | |
|---------------------|-----------------------------|-----------------------------|
| 1. Wendy Leung | 1991-1994 (MSc, Microbiol.) | Eli Lilly, Hong Kong |
| 2. Barbara Steen | 1992-1999 (PhD, Microbiol.) | PDF, Biotechnology Lab, UBC |
| 3. Dorothy Cheung | 1996-1999 (MSc, Pathol.) | Viridae Clinical Sciences |
| 4. Karen Chu | 1997- | |
| 5. Jacqueline Chung | 1997- | |

External Reviewer:

1. Hongwei Yu (U. of Calgary) Nov. 30, 1993 (PhD, Biol. Sc.)
2. Peter Lee (U. of Western Australia) May 19, 1999 (PhD)

PhD Committee Member for:

1. Janet Battershill
2. Eileen Rawling
3. John Coutinho
4. José Rey
5. Robert Forsyth
6. Li Miao
7. Rumi-Lynn Asano

MSc Committee Member for:

1. Jaskamal Girm

Sabbatical Visitors Supervised:

1. Taole Mokoena, MB, D.Phil 1991-1992

Courses Taught:

- | | |
|--------|--|
| 1991-2 | Microbiology 505 |
| 1992-3 | Microbiology 507 |
| 1993-4 | Microbiology 507 |
| 1994-5 | Microbiology 507 |
| 1995-6 | Microbiology 202 (Med. Microbiology segment - 18 hours of lecture to 700 undergraduates) |
| 1996-7 | Microbiology 202 |
| 2002 | Microbiology 507 |

GRANTS APPLIED FOR:

British Columbia Lung Association

"Mechanisms of resistance of *Burkholderia cepacia* to pulmonary host defenses"

\$60,000 2002-2004 (\$30,000 p.a.)

GRANTS RECEIVED:**Various Educational Projects**

\$15,000 Oct.1998- ongoing

Canadian Institute of Health Research

"Role of innate immunity in defense of the lung against bacterial infection"

\$291,000 2002-2005 (97,152 p.a.)

Health Canada H405-0SB471

"Pseudomonas Double-Blind Study"

\$10,000 2001

\$25,000 2001-2002

Department of Western Economic Diversification BXJZ00021

"Plagues and People"

\$20,000 2001

Vancouver Foundation BCM00-0086

"Evaluation of Molecular Diagnostic Techniques in the Management of Febrile Children in the Emergency Room"

\$49,250.00 Dec. 2000 – Dec. 2001 (\$24,625.00 p.a.)

BC Lung Association

"Pathogenesis of *Burkholderia cepacia*"

\$60,000 Oct 2000 - Sept 2002 (\$30,000 p.a.)

Medical Research Council of Canada MT-9462

"The mechanism of nonopsonic phagocytosis by macrophages and polymorphonuclear leukocytes"

\$77,730 1985-1987

- Renewal \$80,382 1987-1989

- Renewal \$180,286 1989-1992

- Renewal \$263,838 1992-1995

- Renewal \$39,960 1995-1996

- Renewal \$239,760 1996-1999 (\$79,920 p.a.)

\$81,518 1999-2000

\$50,949 2000-2001

Canadian Cystic Fibrosis Foundation

"Biological and pathogenic properties of mucoid *Pseudomonas aeruginosa* and its mucoid polysaccharide"

\$26,160 1981-1982

- Renewal \$38,015 1982-1983

- Renewal \$36,442 1983-1984

EXHIBIT "A" (continued)

- Renewal	\$36,496	1984-1985
- Renewal	\$41,080	1985-1986
- Renewal	\$123,984	1986-1989
- Renewal	\$154,593	1989-1992
- Renewal	\$190,500	1992-1995

"Pathogenesis and epidemiology of *Pseudomonas aeruginosa* and *Burkholderia cepacia* in cystic fibrosis"

- Renewal	\$266,424	1995-1998
- Renewal	\$266,399	1998-2001 (1998-99: \$95,133; 1999-2000: \$85,633; 2000-2001: \$85,633)
- Renewal	\$285,000	2001-2004 (\$95,000 p.a.)

Networks of Centres of Excellence (Canadian Bacterial Diseases Network)

"Bacterial diseases: Molecular strategies for the study and control of bacterial pathogens of humans, animals, fish and plants"

\$376,147 1990-1994

- Renewal	\$90,744 p.a.	1994-1996 - Phase I
- Renewal	\$78,114 p.a.	1996-1998 - Phase II

"Strategies for therapy of intracellular pathogens" - Phase III VP6

- Renewal	\$91,300	1998-1999
- Renewal	\$89,108	1999-2000
- Renewal	\$ 98,019.68	2000-2001
- Renewal	\$106,930.56	2001-2002

Canadian C.F. Fdn. Special Programme in Applied Research & Therapy (SPARx1).

"Novel approaches to prevention of *P. aeruginosa* in patients with cystic fibrosis"

\$491,690 p.a.	1996-2002 (with Drs. A. Cantin, W. Finlay, R. Hancock and D. Woods)
DPS portion:	\$126,000 1996-1998 (\$63,000 p.a.)
DPS portion:	\$63,000 1998-1999
DPS portion:	\$99,857 1999-2000
DPS portion:	\$99,857 2000-2001
DPS portion:	\$24,854 2001-2002

Canadian Cystic Fibrosis Foundation

"*Burkholderia cepacia* referral and repository laboratory"

\$20,000 2001-2002

Canadian Cystic Fibrosis Foundation – Clinical Studies Network

\$29,200	1996-1997
\$34,100	1997-1998
\$29,310	1198-1999
\$29,550	1999-2000
\$40,000	2000-2001
\$40,000	2001-2002

Canadian Cystic Fibrosis Foundation - Thompson Family Fund

"*Burkholderia cepacia* infection in patients with cystic fibrosis"

\$35,000 1999-2000

BCY Ventures Inc.

"Characterization of macrophage receptors mediating nonopsonic phagocytosis"

\$213,596 April 2000 - March 2002 (\$106,798 p.a.)

Various Companies

"Study comparing BCSA to OFPBL and PCA for the selection of *Burkholderia cepacia* from respiratory secretions from patients with cystic fibrosis"

\$18,563.10 10/1998 - 02/2002

Peter Wall Institute for Advanced Studies

Exploratory Workshop: "Outsmarting the superbugs: Responding to the antibiotic resistance crisis"

\$59,840 1998-2002

Vancouver Foundation BCM97-0016

"Antibiotic Resistance Education Project"

\$32,100 1998-1999

BC's Children's Hospital - 1998 Telethon

"The Best Medicine: Understanding antibiotic resistance"

\$26,900 1998-1999

Canadian CF Foundation Clinical Studies Network Workshop

\$6,256 1998

Abbott

"Penicillin Resistant *Streptococcus Pneumoniae*"

\$10,000 1998

?? BC Children's Hospital

Interest account from endowment

\$

BC Medical Services Foundation

"Antibiotic Resistance Education Project"

\$50,000 June 1, 1997 - May 31, 1998

BC Lung Association

"The mechanisms of respiratory tract infection of *Burkholderia cepacia*"

\$22,100 1997 -1998

- Renewal \$22,350 1998-1999

BC Lung Association

Career Development Award - Eshwar Mahenthiralingam, PhD

\$20,000 Dec. 1997 - Nov. 1998

Dextran Products Ltd.

"The role of dextran sulphate and glycoconjugates in the prevention and therapy of *Pseudomonas aeruginosa* infections in patients with cystic fibrosis" (contract)

\$688,793 1994-1998

Medical Research Council

"Molecular definition of mycobacterial virulence factors"
\$120,327 1994-1998 (with Dr. Richard Stokes).

Medical Research Council

"New approaches to prevention of infection with *Pseudomonas aeruginosa* in patients with cystic fibrosis"
\$32,738 1994-1997 (with Drs. Randall Irvin and David Bundle).

Glaxo Wellcome (Canada) Inc.

"Strategies for tuberculosis therapy" (contract)
\$250,719 1994-1997 (with Drs. Julian Davies, Richard Stokes, Francis Nano and Neil Reiner).
Rick's portion: \$250,719 1995-1998

Genentech, Inc.

"The role of interferon-gamma in host defense against extracellular pathogens"
\$78,039 1995-1996

Alpha-Beta Technology Inc.

"Effect of glucans on growth of *Mycobacterium tuberculosis* in mice" (contract)
\$3,855 1995 (P.I. Dr. Richard Stokes)

Health Protection Branch, Health and Welfare Canada

"Repository of microorganisms (*Pseudomonas spp.*) (BT001-09)" (contract)
\$161,320 1992-1995

Health Protection Branch, Health and Welfare Canada

"Assessment of virulence factors in *Pseudomonas aeruginosa* and *P. cepacia*" (contract)
\$47,400 1991-1993

BC Lung Association

"Factors controlling resistance and susceptibility to mycobacterial infections in mice"
\$15,000 1991-1992

BC's Children's Hospital - 1991 Telethon

"Enhancement of neutrophil function by cytokines following bone marrow transplantation"
\$40,430 1991-1992

TB and Chest Disabled Veterans Association

Equipment Grant
\$2,923 1991

Canadian Cystic Fibrosis Foundation Scholarship

\$60,000-68,000 p.a. 1987-1992

Detweiler Travel Fellowship, Royal College of Physicians and Surgeons of Canada

\$15,000 1989-1990

Health and Welfare Canada, National Health Research and Development Program.

EXHIBIT "A" (continued)

"The epidemiology of *Pseudomonas aeruginosa* colonization and infection in patients with cystic fibrosis" \$32,230 1987-1988

BC Health Care Research Foundation.

"The epidemiology of *Pseudomonas aeruginosa* infection in patients with cystic fibrosis"

\$33,000 1986-1987

- Renewal \$33,000 1987-1988

BC Medical Services Fdn. and Research Division of B.C.'s Children's Hospital. (Matching grant)

"Evaluation of alginase in the therapy of mucoid *Pseudomonas aeruginosa* lung infections"

\$60,000 1986-1988

BC Medical Services Foundation/Canadian Lung Association

"Purification of the *Pseudomonas aeruginosa* alginase"

\$37,000 1983-1986 (1983-84: \$7,500; 1985-86: \$29,500)

Faculty of medicine Research Coordinating Committee – 65-1865

"*Pseudomonas aeruginosa* in Cystic Fibrosis Patients"

\$5,000 1983-1984

BC Lung Association

"The epidemiology of *Pseudomonas aeruginosa* colonization in cystic fibrosis"

\$43,333 1982-1984

BC Medical Services Foundation

"Purification and characterization of the exopolysaccharide from mucoid *Pseudomonas aeruginosa*"

\$31,400 1981-1982

Cystic Fibrosis Foundation (U.S.)

"Biological and pathogenic properties of mucoid *Pseudomonas aeruginosa* and its slime polysaccharide" US\$65,000 1980-1982

Various Drug Companies

"Antibacterial activity of antibiotics in Cystic Fibrosis"

\$3,000 1982-1983

\$12,830 1983-1984

BC Medical Services Foundation

"Purification and characterization of exopolysaccharide from *Pseudomonas aeruginosa*"

\$31,400 1981-1982

BC Medical Services Foundation

"Biological and pathogenic properties of mucoid *Pseudomonas aeruginosa* and its mucoid polysaccharide"

\$16,400 1981

Woodward Foundation - Equipment grant.

\$21,840 1981-1982

EXHIBIT "A" (continued)

FELLOWSHIPS RECEIVED: (1995 - present)

Canadian Cystic Fibrosis Foundation

Post-doctoral Fellowship – Andrew Currie, PhD
\$35,000 p.a. 2001 – 2003

Wellcome Trust

Grant for research expenses during Post-doctoral Fellowship – Donald Davidson, PhD
\$43,500 2000 – 2001
\$25,500 2001 – 2002

BC Research Institute for Children's & Women's Health

Bertram M. Hoffmeister Post-doctoral Fellowship - Leah Macfadyen, PhD
\$26,790 1999-2000

BC Research Institute for Children's & Women's Health

Post-doctoral Fellowship - Xiaowen Liao Bina, PhD
\$28,650 1998-1999

Canadian Cystic Fibrosis Foundation

Post-doctoral Fellowship – Mary Macdonald, PhD
\$27,100 1995-1996
\$29,680 1996-1997

BC Lung Association

Post-doctoral Fellowship – Mary Macdonald, PhD
\$13,750 1995

Patents:

1. **Speert DP**, Barghouthi S, and Gordon S: "Factors which regulate macrophage antibacterial activity" **US Patent #5,441,938** - August 15, 1995
2. **Speert DP** and Usher T: "Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans" **US Patent #5,514,665** - May 7, 1996
3. King M, **Speert DP**: Use of dextran and other polysaccharides to improve mucus clearance. US patent application. **US Patent #6,339,075** – January 15, 2002.

BIBLIOGRAPHY

I. PAPERS

1. Steffensen DM, Chu EHY, **Speert DP**, Wall PM, Meilinger K, Kelch RP: Partial trisomy of the long arm of human chromosome 1 as demonstrated by *in situ* hybridization with 5S ribosomal RNA. *Human Genetics*, 36: 25-33, 1977.
2. Magilavy DB, **Speert DP**, Silver TM, Sullivan DB: Mucocutaneous lymph node syndrome: Report of two cases complicated by gallbladder hydrops and diagnosed by ultrasound. *Pediatrics*, 61: 699-702, 1978.
3. **Speert DP**, Silva J, Jr: Abnormalities of *in vitro* lymphocyte response to mitogens in diabetic children during acute ketoacidosis. *Am J Dis Child*, 132: 1014-1017, 1978.
4. **Speert DP**, Britt WJ, Kaplan EL: Tick-borne tularemia presenting as ulcerative lymphadenitis. *Clin Pediatr*, 18: 239-241, 1979.
5. Ancona RJ, McAuliffe J, Thompson TR, **Speert DP**, Ferrieri P: Group B streptococcal sepsis with osteomyelitis and arthritis: its occurrence with acute heart failure. *Am J Dis Child*, 133: 919-920, 1979.
6. **Speert DP**, Wannamaker LW, Gray ED, Clawson CC: Bactericidal effect of oleic acid on group A streptococci: Mechanism of action. *Infect Immun* 26: 1202-1210, 1979.
7. **Speert DP**, Munson D, Mitchell C, Johnson DE, Thompson TR, Ferrieri P, Wannamaker LW: *Mycobacterium chelonae* sepsis in a premature infant. *J Pediatr*, 96: 681-683, 1980.
8. **Speert DP**, Wannamaker LW: Susceptibility of Group A streptococci to oleic acid and ultraviolet light: Comparison of strains from throat and skin. *J Lab Clin Med*, 96: 252-257, 1980.
9. Johnson DE, Bass JL, Thompson TR, Foker JE, **Speert DP**, Kaplan EL: Candida septicemia and a right atrial mass secondary to umbilical vein catheterization. *Am J Dis Child*, 135: 275-277, 1981.
10. **Speert DP**, Wannamaker LW, Quie PG: Enhanced phagocytosis of group A streptococci M type 6 by oleic acid. *J Infect Dis*, 143: 570-577, 1981.
11. **Speert DP**: Infections of the lung in cystic fibrosis. *British Columbia Med J*, 23: 475-477, 1981.
12. **Speert DP**, Lawton D, Damm S: Communicability of *Pseudomonas aeruginosa* in a cystic fibrosis summer camp. *J Pediatr*, 101: 227-229, 1982.
13. Laxer R, **Speert DP**, Petty R: Kawasaki disease: approach to diagnosis and management. *British Columbia Med J*, 25: 81-83, 1983.
14. Hancock REW, Mutharia LM, Chan L, Darveau RP, **Speert DP**, Pier GB: *Pseudomonas aeruginosa* isolates from patients with cystic fibrosis: a class of serum-sensitive, non-typable strains deficient in lipopolysaccharide O side-chains. *Infect Immun*, 42: 170-177, 1983.
15. Hancock REW, Mouat ECA, **Speert DP**: Quantitation and identification of antibodies to outer membrane proteins of *Pseudomonas aeruginosa* in the sera of patients with cystic fibrosis. *J Infect Dis* 149: 220-226, 1984.
16. **Speert DP**, Eftekhari F, Puterman ML: Nonopsonic phagocytosis of strains of *Pseudomonas aeruginosa* from cystic fibrosis patients. *Infect Immun* 43: 1006-1011, 1984.
17. **Speert DP**, Lawton D, Mutharia L: Antibody to *Pseudomonas aeruginosa* mucoid exopolysaccharide and to sodium alginate in cystic fibrosis serum. *Pediatr Res* 18: 431-433, 1984.
18. **Speert DP**: Host defenses in cystic fibrosis: modulation by *Pseudomonas aeruginosa*. *Survey and Synthesis of Pathology Research* 4: 14-33, 1985.
19. Cabral DA, Johnson HW, Coleman GU, Nigro M, **Speert DP**: Tuberculous epididymitis as a cause of testicular pseudomalignancy in two young children. *Pediatr Infect Dis* 4: 59-62, 1985.
20. Burdge DB, Scheifele D, **Speert DP**: Serious *Pasteurella multocida* infections from lion and tiger bites. *J Am Med Assoc* 253: 3296-3297, 1985.

21. **Speert DP**, Silverstein SC: Phagocytosis of unopsonized zymosan by human monocyte-derived macrophages: maturation and inhibition by mannan. *J Leukocyte Biol* 38: 655-658, 1985.
22. Paranchych W, Sastry PA, Volpel K, Loh BA, **Speert DP**: Fimbriae (pili): molecular basis of *Pseudomonas aeruginosa* adherence. *Clin Invest Med* 9: 119-123, 1986.
23. **Speert DP**, Loh BA, Cabral DA, Salit IE: Nonopsonic phagocytosis of nonmucoid *Pseudomonas aeruginosa* by human neutrophils and monocyte-derived macrophages is correlated with bacterial piliation and hydrophobicity. *Infect Immun* 53: 207-212, 1986.
24. Pier GB, DesJardins D, Aguilar T, Barnard M, **Speert DP**: Polysaccharide surface antigens expressed by nonmucoid isolates of *Pseudomonas aeruginosa* from cystic fibrosis patients. *J Clin Microbiol* 24: 189-196, 1986.
25. **Speert DP**, Campbell ME: Hospital epidemiology of *Pseudomonas aeruginosa* from patients with cystic fibrosis. *J Hospital Infection* 9: 11-21, 1987.
26. Cabral DA, Flodmark O, Farrell K, **Speert DP**: A prospective study of computed tomography in acute bacterial meningitis. *J Pediatr* 111: 201-205, 1987.
27. **Speert DP**, Dimmick JE, Pier GB, Saunders JM, Hancock REW, Kelly N: An immunohistological evaluation of *Pseudomonas aeruginosa* infection in two patients with cystic fibrosis. *Ped Res* 22: 743-747, 1987.
28. Cabral DA, Loh BA, **Speert DP**: Mucoid *Pseudomonas aeruginosa* resists nonopsonic phagocytosis by human neutrophils and macrophages. *Ped Res* 22: 429-31, 1987.
29. Pier GB, Saunders JM, Ames P, Auerbach H, Edwards MS, Goldfarb J, **Speert DP**, Hurwitch S: Opsonophagocytic killing antibody to *Pseudomonas aeruginosa* mucoid exopolysaccharide in older noncolonized cystic fibrosis patients. *N Engl J Med* 317: 793-798, 1987.
30. Battershill JL, **Speert DP**, Hancock REW: Use of monoclonal antibodies against protein F of *Pseudomonas aeruginosa* as opsonins for phagocytosis by macrophages. *Infect Immun* 55: 2531-2533, 1987.
31. Stiver HG, Zachidniak K, **Speert DP**: Inhibition of polymorphonuclear chemotaxis by the mucoid exopolysaccharide of *Pseudomonas aeruginosa*. *Clin Invest Med* 11: 247-252, 1988.
32. Pasloske BL, Joffe AM, Sun Q, Volpel K, Paranchych W, Eftekhari F, **Speert DP**: Serial isolates of *Pseudomonas aeruginosa* from a cystic fibrosis patient have identical pilin sequences. *Infect Immun* 56: 665-672, 1988.
33. **Speert DP**, Wright SD, Silverstein SC, Mah B: Functional characterization of human macrophage receptors for *in vitro* phagocytosis of unopsonized *Pseudomonas aeruginosa*. *J Clin Invest* 82: 872-879, 1988.
34. Lam JS, MacDonald LA, Kropinski AM, **Speert DP**: Characterization of non-typable strains of *Pseudomonas aeruginosa* from cystic fibrosis patients by means of monoclonal antibodies and SDS-polyacrylamide gel electrophoresis. *Serodiagnosis and Immunotherapy* 2: 365-374, 1988.
35. Eftekhari F, **Speert DP**: Alginate treatment of mucoid *Pseudomonas aeruginosa* enhances phagocytosis by human monocyte-derived macrophages. *Infect Immun* 56: 2788-2793, 1988.
36. Campbell ME, Farmer SW, **Speert DP**: A new selective medium for *Pseudomonas aeruginosa* with phenanthroline and 9-chloro-9-[4-(diethylamino)phenyl]-9,10-dihydro-10-phenylacridine (C-390). *J Clin Microbiol* 26: 1910-1912, 1988.
37. **Speert DP**, Campbell ME, Farmer SW, Volpel K, Paranchych W: Use of a pilin gene probe to study molecular epidemiology of *Pseudomonas aeruginosa*. *J Clin Microbiol* 27: 2589-2593, 1989.
38. **Speert DP**: Prevention of severe lower respiratory infections in patients with cystic fibrosis. *Seminars in Respiratory Infections* 4: 266-271, 1989.
39. Pike MG, Wong PKH, Bencivenga R, Flodmark O, Cabral DA, **Speert DP**, Farrell K: Electrophysiological studies, computed tomography, and neurologic outcome in acute bacterial meningitis. *J Pediatr* 116: 702-706, 1990.
40. Bayer AS, Eftekhari F, Tu J, Nast CC, **Speert DP**: Oxygen-dependent upregulation of mucoid exopolysaccharide (alginate) production in *Pseudomonas aeruginosa*. *Infect Immun* 58: 1344-1349, 1990.

41. **Speert DP**, Farmer SW, Campbell ME, Musser JM, Selander RK, Kuo S: Conversion of *Pseudomonas aeruginosa* to the phenotype characteristic of strains from patients with cystic fibrosis. *J Clin Microbiol* 28: 188-194, 1990.
42. Bayer AS, **Speert DP**, Park S, Tu J, Witt M, Nast CC, Norman DC: Functional role of mucoid exopolysaccharide (alginate) in antibiotic-induced and polymorphonuclear leukocyte-mediated killing of *Pseudomonas aeruginosa*. *Infect Immun* 59: 302-308, 1991.
43. **Speert DP**, Thorson L: Suppression by human recombinant gamma-interferon of *in vitro* macrophage receptor-mediated phagocytosis. *Infect Immun* 59: 1893-1898, 1991.
44. Wilson E, Thorson L, **Speert DP**: Enhancement of macrophage superoxide anion production by amphotericin B. *Antimicrob Agent Chemother* 35: 796-800, 1991.
45. Phillips P, Forbes JC, **Speert DP**: Disseminated infection with *Pseudallescheria boydii* in a patient with chronic granulomatous disease: response to gamma-interferon plus antifungal chemotherapy. *Pediatr Infect Dis J* 10: 536-539, 1991.
46. Conly ME, **Speert DP**: Human neonatal monocyte-derived macrophages and neutrophils exhibit normal *in vitro* receptor-mediated phagocytosis and superoxide anion production. *Biology of the Neonate*. 60: 361-366, 1991.
47. **DP**: Sylvatic hydatid disease in children: case reports and review of endemic *Echinococcus granulosus* infection in Canada and Alaska. *Pediatr Infect Dis J* 11: 322-326, 1992.
48. **Speert DP**, Campbell ME, Davidson AGF, Wong LTK: *Pseudomonas aeruginosa* colonization of the **Speert DP**, Gordon S: Phagocytosis of unopsonized *Pseudomonas aeruginosa* by murine macrophages is a two-step process requiring glucose. *J Clin Invest* 90: 1085-1092, 1992.
49. Finlay J, **Speert** gastrointestinal tract in patients with cystic fibrosis. *J Infect Dis* 167: 226-229, 1993.
50. **Speert DP**: Phagocytosis of *Pseudomonas aeruginosa* by macrophages: receptor-ligand interactions *Trends in Microbiology* 1: 217-221, 1993.
51. Stokes RW, Haidl ID, Jefferies WA, **Speert DP**: Mycobacteria-macrophage interactions: macrophage phenotype determines the nonopsonic binding of *Mycobacterium tuberculosis* to murine macrophages. *J Immunol* 151: 7067-7076, 1993.
52. **Speert DP** (principal author) and the Clinic Subcommittee, Canadian Cystic Fibrosis Foundation. Epidemiology of *Pseudomonas cepacia* in cystic fibrosis. *Can J Infect Dis* 4: 163-5, 1993.
53. Clinic Subcommittee, Canadian Cystic Fibrosis Foundation. Microbiological processing of respiratory specimens from patients with cystic fibrosis. *Can J Infect Dis* 4: 166-9, 1993.
54. **Speert DP** (principal author) and the International *Pseudomonas aeruginosa* Typing Study Group. A multicenter comparison of methods for typing strains of *Pseudomonas aeruginosa* predominantly from patients with cystic fibrosis. *J Infect Dis* 169: 134-142, 1994.
55. Dasgupta T, deKievit TR, Masoud H, Altman E, Richards JC, Sadoskaya I, **Speert DP**, Lam JS: Characterization of lipopolysaccharide-deficient mutants of *Pseudomonas aeruginosa* derived from serotypes O3, O5 and O6. *Infect Immun* 62: 809-817, 1994.
56. Mahenthiralingam E, Campbell ME, **Speert DP**: Nonmotility and phagocytic resistance of *Pseudomonas aeruginosa* strains from chronically colonized patients with cystic fibrosis. *Infect Immun* 62: 596-605, 1994.
57. **Speert DP**: Infection control issues for patients with cystic fibrosis. *Rep Pediatr Infect Dis* 4: 15-16, 1994.
58. **Speert DP**, Bond M, Woodman R, Curnutte JT: Infection with *Pseudomonas cepacia* in chronic granulomatous disease: the role of nonoxidative killing by neutrophils in host defense. *J Infect Dis* 170: 1524-1531, 1994.
59. Burdge DR, Noble MA, Campbell ME, Krell VL, **Speert DP**: *Xanthomonas maltophilia* misidentified as *Pseudomonas cepacia* in cultures of sputum from patients with cystic fibrosis: A diagnostic pitfall with major clinical implications. *Clin Infect Dis* 20: 445-448, 1995.
60. Barghouthi S, Everett KDE, **Speert DP**: Nonopsonic phagocytosis of *Pseudomonas aeruginosa* requires facilitated transport of D-glucose by macrophages. *J Immunol* 154: 3420-3428, 1995.
61. **Speert DP**, Petty RE: Poststreptococcal arthritis. *Can J Infect Dis* 6: 133-135, 1995.

62. Stokes RW, **Speert DP**: Lipoarabinomannan inhibits nonopsonic binding of *Mycobacterium tuberculosis* to murine macrophages. *J Immunol* 155: 1361-1369, 1995
63. **Speert DP**: The use of Bacille Calmette-Guerin (BCG) vaccination in children. *Can J Infect Dis* 6: 232-233, 1995
64. Mahenthiralingam E, **Speert DP**: Nonopsonic phagocytosis of *Pseudomonas aeruginosa* by macrophages and polymorphonuclear leukocytes requires the presence of the bacterial flagellum. *Infect Immun* 63: 4519-4523, 1995
65. Marklund B-I, **Speert DP**, Stokes RW: Gene replacement through homologous recombination in *Mycobacterium intracellulare*. *J Bacteriol* 177: 6100-6105, 1995
66. Cham B, Rogers P, Chan KW, **Speert DP**: Neutrophil function in pediatric patients following bone marrow transplantation. *Intl J Ped Hem/Onc* 3: 75-82, 1996
67. Everett KDE, Barghouthi S, **Speert DP**: *In vitro* culture of murine peritoneal and alveolar macrophages modulates phagocytosis of *Pseudomonas aeruginosa* and glucose transport. *J Leuk Biol*, 59: 539-544, 1996
68. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, **Speert DP**: Random amplified polymorphic DNA typing of *Pseudomonas aeruginosa* isolates recovered from patients with cystic fibrosis. *J Clin Microbiol*, 34: 1129-1135, 1996
69. Mahenthiralingam E, Campbell ME, Henry DA, **Speert DP**: Epidemiology of *Burkholderia cepacia* infection in patients with cystic fibrosis: Analysis by random amplified polymorphic DNA fingerprinting. *J Clin Microbiol*, 34: 2914-2920, 1996
70. **Speert DP** (principal author): Antimicrobial resistance: Implications for therapy of infection with common childhood pathogens. *Can J Infect Dis*, 7: 169-173, 1996 (Also published in *Paediatr Child Health*, 1: 51-55, 1996)
71. Davies D, Langley JM, **Speert DP**, for PICNIC: Rating authors' contributions to collaborative research: The PICNIC survey of university departments of pediatrics. *Can Med Assoc J* 155: 877-882, 1996
72. Barghouthi S, Guerdoud L, **Speert DP**: Inhibition by dextran of *Pseudomonas aeruginosa* adherence to epithelial cells. *Am J Respir Crit Care Med*, 154: 1788-1793, 1996
73. Henry DA, Campbell ME, LiPuma JJ, **Speert DP**: Identification of *Burkholderia cepacia* isolates from patients with cystic fibrosis and use of a simple new selective medium. *J Clin Microbiol*. 35: 614-619, 1997
74. Mahenthiralingam E, Simpson DA, **Speert DP**: Identification and characterization of a novel DNA marker associated with epidemic *Burkholderia cepacia* strains recovered from patients with cystic fibrosis. *J Clin Microbiol*. 35: 808-816, 1997
75. **Speert DP**, Wong SYC, Macdonald M, Sargeant R: Modulation of macrophage function for defence of the lung against *Pseudomonas aeruginosa*. *Behring Inst. Mitt.* 98: 274-282, 1997
76. **Speert DP**: Treatment of group A streptococcal pharyngitis. *Can J Infect Dis* 8: 17-18, 1997. (Also published in *Paediatr Child Health* 2: 97-98, 1997)
77. **Speert DP**: Controlling antibiotic resistance: An integrated action plan for Canadians. *Can J Infect Dis* 8: 186-187, 1997. (Also published in *Paediatr Child Health* 2: 250-251, 1997)
78. Woods DE, Lam JS, Paranchych W, **Speert DP**, Campbell M, Godfrey AJ: Correlation of *Pseudomonas aeruginosa* virulence factors from clinical and environmental isolates with pathogenicity in the neutropenic mouse. *Can. J. Microbiol.* 43: 541-551, 1997
79. Dohil M, Prendiville JS, Crawford RI, **Speert DP**: Cutaneous manifestations of chronic granulomatous disease: A report of four cases and review of the literature. *J. Am. Acad. Dermatol.* 36: 899-907, 1997
80. Feng W., Garrett H, **Speert DP**, King M. Improved clearability of cystic fibrosis sputum with dextran treatment *in vitro*. *Am J Respir Crit Care Med*. 157: 710-714, 1998
81. Stokes RW, Thorson LM, **Speert DP**. Nonopsonic and opsonic association of *Mycobacterium tuberculosis* with resident alveolar macrophages is inefficient. *J. Immunol.* 160: 5514-5521, 1998

82. **Speert DP.** Group A streptococcal carriage: Can the troll be tamed? *Can. J. Infect. Dis.* 9: 205-206, 1998; (Also published in *Paediatr. Child Health* 3: 229-230, 1998)
83. Wong SYC, Guerdoud LM, Cantin A, **Speert DP.** Glucose stimulates phagocytosis of unopsonized *Pseudomonas aeruginosa* by cultivated human alveolar macrophages. *Infect. Immun.* 67: 16-21, 1999
84. Henry D, Campbell M, McGimpsey C, Clarke A, Loudon L, Burns JL, Roe MH, Vandamme P, **Speert D.** Comparison of isolation media for recovery of *Burkholderia cepacia* complex from respiratory secretions of patients with cystic fibrosis. *J. Clin. Microbiol.* 37: 1004-1007, 1999
85. Bryan R, Feldman M, Jawetz SC, Rajan S, DiMango E, Tang HB, Scheffler L, **Speert DP, Prince A.** The effects of aerosolized dextran in a mouse model of *Pseudomonas aeruginosa* pulmonary infection. *J. Infect. Dis.* 179: 1449-1458, 1999
86. **Speert DP, Steen B, Halsey K, Kwan E.** A murine model for infection with *Burkholderia cepacia* with sustained persistence in the spleen. *Infect. Immun.* 67: 4027-4032, 1999
87. Hirakata Y, Finlay BB, Kohno S, Kamihira S, **Speert DP.** Penetration of clinical isolates of *Pseudomonas aeruginosa* through MDCK epithelial cell monolayers. *J. Infect. Dis.* 181: 765-769, 2000
88. Vandamme P, Mahenthiralingam E, Holmes B, Coenye T, Hoste B, de Vos P, Henry D, **Speert DP.** Identification and population structure of *Burkholderia stabilis* sp. nov (formerly *Burkholderia cepacia* genomovar IV). *J. Clin. Microbiol.* 38: 1042-1047, 2000
89. Finlay WH, Lange CF, King M, **Speert DP.** Lung delivery of aerosolized dextran. *Am. J. Resp. Crit. Care Med.* 161: 91-97, 2000
90. Simpson DA, **Speert DP.** RpmA is required for nonopsonic phagocytosis of *Pseudomonas aeruginosa*. *Infect. Immun.*, 68: 2493-2502, 2000
91. Aaron S, Ferris W, Henry DA, **Speert DP, MacDonald N.** Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with *Burkholderia cepacia*. *Am. J. Resp. Crit. Care Med.* 161: 1206-1212, 2000
92. **Speert DP, Simpson DA.** Phagocytosis of *Pseudomonas aeruginosa*, In *Advances in Cell and Molecular Biology of Membranes and Organelles*" Gordon & Tartakoff (ed.) JAI Press, Inc. Vol. 6 pp. 159-172, 1999
93. Cheung, DOY, Halsey K, **Speert DP.** The role of pulmonary alveolar macrophages in defense of the lung against *Pseudomonas aeruginosa*. *Infect. Immun.* 68: 4584-4592, 2000
94. Mahenthiralingam E, Coenye T, Chung JW, **Speert DP, Govan JRW, Taylor, Vandamme P.** A diagnostically and experimentally useful panel of strains from the *Burkholderia cepacia* complex. *J. Clin. Microbiol.* 38: 910-913, 2000
95. **Speert DP, Heale J.-P.** Macrophages and *Pseudomonas aeruginosa*. *Clin. Microbiol. Infect.* (in press)
96. **Speert DP.** Understanding *Burkholderia cepacia*: genomovars, virulence and epidemics. *Infections in Medicine.* 18: 49-56, 2001
97. Paluck E, Katzenstein D, Frankish CJ, Herbert C, Milner R, **Speert DP, Chambers K.** Prescribing practices and attitudes toward giving children antibiotics. *Canadian Family Physician.* 47: 521-527, 2001
98. Campbell M, Mahenthiralingam E, **Speert, DP.** Evaluation of Random Amplified Polymorphic DNA Typing of *Pseudomonas aeruginosa*. *J. Clin. Microbiol.* 38: 4614-4615, 2000
99. Hancock REW, **Speert DP.** Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and impact on treatment options (minireview). *Drug Resistance Updates* 3: 247-255, 2000.
100. Pollard A, Heale J-P, Tsang A, Massing B, **Speert DP.** Nonopsonic phagocytosis of *Pseudomonas aeruginosa*: insights from an infant with leucocyte adhesion deficiency. *Ped. Infect. Dis. J.*, 20: 452-454, 2001.
101. Saiman L, MacDonald N, Burns JL, Hoiby N, **Speert DP, Weber D.** Infection control in cystic fibrosis: Practical recommendations for the hospital, clinic, and social settings. *Am J Infect Control* 28: 381-5, 2000.

102. Coenye T, Mahenthiralingam E, Henry D, LiPuma JL, Laevens S, Gillis M, **Speert DP**, Vandamme P. *Burkholderia ambifaria* sp. nov., a novel member of the *Burkholderia cepacia* complex including biocontrol and cystic fibrosis-related isolates. *International Journal of Systemic and Evolutionary Microbiology*. 51:1481-1490, 2001.
103. Henry DA, Mahenthiralingam E, Vandamme P, Coenye T, **Speert DP**. Phenotypic methods for determining genomovar status of the *Burkholderia cepacia* complex. *J. Clin. Microbiol.* 39: 1073-1078, 2001.
104. Chiu C-H, Ostry A, **Speert DP**. Invasion of murine respiratory epithelial cells in vivo by *Burkholderia cepacia*. *J. Med. Microbiol.* 50:594-601, 2001.
105. Heale J-P, **Speert DP**. Protein kinase C agonists enhance phagocytosis of *P. aeruginosa* by murine alveolar macrophages. *J. Leuk. Biol.* 69: 158-160, 2001
106. Coenye T, LiPuma JJ, Henry D, Hoste B, Vandemeulebroecke K, Gillis M, **Speert DP**, Vandamme P. *Burkholderia cepacia* genomovar VI, a new member of the *Burkholderia cepacia* complex isolated from cystic fibrosis patients. *Int. J. Syst. Evol. Microbiol.* 51: 271-279, 2001
107. Heale, J-P, Pollard A, Crookall K, Stokes, RW, Simpson D, Tsang A, Massing B, **Speert, DP**. Two distinct receptors mediate nonosponic phagocytosis of different strains of *Pseudomonas aeruginosa*. *J. Infect. Dis.* 183: 1214-20, 2001.
108. Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LTK, Davidson AGF, Wilcox PG, Nakielna B, **Speert DP**. Infection with *Burkholderia cepacia* complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace *Burkholderia multivorans*. *Clin. Infect. Dis.* 33:1469-1475, 2001.
109. Chiu CH, Wong S, Hancock REW, **Speert DP**. Adherence of *Burkholderia cepacia* to respiratory tract epithelial cells and inhibition with dextrans. *Microbiol.* 147:2651-2658, 2001.
110. Greenberg D, **Speert DP**, Mahenthiralingam E, Henry DA, Campbell ME, Scheifele DW. Emergence of Penicillin-Non-Susceptible *Streptococcus Pneumoniae* Invasive Clones In Canada. *J. Clin. Microbiol.* 40: 68-74, 2002.
111. **Speert DP**, Henry D, Vandamme P, Corey M, Mahenthiralingam E. Epidemiology of *Burkholderia cepacia* in Patients with Cystic Fibrosis in Canada: Geographical Distribution and Clustering of Strains. *Emerg. Infect. Dis.* 8:181-187, 2002.
112. Chu KK, Davidson DJ, Halsey TK, Cheung JW, **Speert DP**. Differential persistence of the *Burkholderia cepacia* complex in a murine model of pulmonary infection. *Infect. Immun.* 70:2715-2720, 2002.
113. Pollard AJ, Probe G, Trombley C, Castell A, Whitehead S, Bigham JM, Champagne S, Isaac-Renton J, Tan R, Guiver M, Borrow R, **Speert DP**, Thomas E. Evaluation of a diagnostic PCR for *Neisseria meningitides* in North America and field experience during an outbreak. *Archives of Pathology & Laboratory Medicine*, (in press).
114. Vandamme P, Henry D, Coenye T, Nzula S, Vancanneyt M, LiPuma JJ, **Speert DP**, Govan JRW, Mahenthiralingam E. *Burkholderia anthina* sp. Nov. and *Burkholderia pyrrocinia*, two additional *Burkholderia cepacia* complex bacteria, may confound test results of new molecular diagnostic tools. *FEMS Immunology and Medical Microbiology*. 33:143-149, 2000
115. **Speert DP**, Campbell, ME, Henry DA, Milner R, Taha F, Gravelle A, Davidson AGF, Wong LTK, Mahenthiralingam E. Epidemiology of *Pseudomonas aeruginosa* Infection in Patients With Cystic Fibrosis in British Columbia Canada: Low Risk of Patient to Patient Spread." *American Journal of Respiratory and Critical Care Medicine* (in press)
116. **Speert DP**, Molecular epidemiology of *Pseudomonas aeruginosa*. *Frontiers in Bioscience* (in press).

117. Hirakata Y, Srikumar R, Poole K, Gotoh N, Suematsu T, Kohno S, Kamihira S, Hancock, REW, **Speert DP**. Multidrug efflux plays an important role in the invasiveness of *Pseudomonas aeruginosa* J. Exp. Med. 196:109-118, 2002
118. Soni R, Marks G, Henry DA, Robinson M, Moriarty C, Parsons S, Taylor P, Mahenthiralingam E, **Speert DP**, Bye PT. Effect of *Burkholderia cepacia* infection in the clinical course of patients with cystic fibrosis: Thorax (in press)
119. Chung JW, Altman E, Beveridge TJ, **Speert DP**. Colonial Morphology of *Burkholderia cepacia* Complex Genomovar III: Implications in Exopolysaccharide Production, Pilus Expression and Persistence in the Mouse. Infect. Immun. (in press)
120. Conway BD, Venu V, **Speert DP**. Biofilm formation and acyl-hoserine lactone production in the *Burkholderia cepacia* complex . J. Bacteriol. (in press).

Submitted:

1. Pollard AJ, Currie A, Rosenberger C, Heale J, Liu S, Finlay BB, **Speert DP**. Human phagocyte activation by *Pseudomonas aeruginosa* (submitted).
2. **Speert, DP**. Advances in *Burkholderia cepacia* Complex. (Submitted to Pediatric Respiratory Reviews - March 2002)

II. BOOKS and CHAPTERS

1. **Speert DP**, Hancock REW (ed). *Pseudomonas aeruginosa*: New therapeutic approaches from basic research. Antibiotics and Chemotherapy, Vol. 36. S. Karger, Basel, pp. 176, 1985
2. **Speert DP**, Loh BA, Cabral DA, Eftekhari F: Opsonin independent phagocytosis of *Pseudomonas aeruginosa*. Antibiot. Chemother. 36 :88-94, 1985
3. **Speert DP**: Pneumonia. In *Handbook of Pediatric Emergencies*, G. Baldwin (ed.). Little Brown and Company, Toronto, pp. 255-259, 1989
4. **Speert DP**: Encephalitis. In *Handbook of Pediatric Emergencies*, G. Baldwin (ed). Little Brown and Company, Toronto, pp. 253-259, 1989
5. **Speert DP**: The acute sore throat: A diagnostic enigma. Canadian J of Diagnosis. 6:79-93, 1989
6. **Speert DP**: Macrophages in bacterial infection. In *The Natural Immune System* Volume II: The Macrophage, Lewis CE and O'D McGee J (ed.). Oxford University Press, pp. 217-263, 1992
7. **Speert DP**: *Pseudomonas aeruginosa* - Phagocytic Cell Interactions. In *Pseudomonas aeruginosa as an Opportunistic Pathogen*, Friedman H and Campa M, Bendinelli M and Friedman H (ed.). Plenum Press, New York, pp. 163-168, 1993
8. **Speert DP**: Tuberculosis. In *Infectious Diseases of Children*, 9th Edition, Krugman S, Katz S, Wilfert C and Gershon A (ed). Mosby Year Book, pp. 551-72, 1992
9. **Speert DP**, Gold R: "Information for Sharing", In *Well Beings*, Canadian Pediatric Society, pp. 903-934, 1992
10. "Managing Illness", In *Well Beings*, Canadian Pediatric Society, pp. 115-201, 1992 (with Ron Gold)
11. **Speert DP**: *Pseudomonas aeruginosa* infections in patients with cystic fibrosis. In *Pseudomonas aeruginosa: Infections and Treatment*. Baltch AL and Smith RP (ed). Marcel Dekker, New York, pp. 183-236, 1994
12. Rest RF, **Speert DP**: Measurement of nonopsonic phagocytic killing by human and mouse phagocytes. Meth. Enzymol. 236: 91-108, 1994
13. **Speert DP**: Sore Throat. In *Therapeutic Choices*, Gray J (ed). Canadian Pharmaceutical Association, pp. 65-84, 1995

14. Mahenthiralingam E, **Speert DP**: Microbial virulence and pathogenesis in cystic fibrosis. In *Cystic Fibrosis Pulmonary Infections: Lessons Learned from Around the World*. Bauernfeind A, Marks MI, Standvik B (ed.). Birkhauser Verlag AG, Basel, Chap. 5, pp. 65-84, 1996
15. Hancock REW, **Speert DP**. Antibiotics for *Pseudomonas* and related infections. In *Cystic Fibrosis - Current Topics*, Vol. 3, Dodge JA, Brock DJH, Widdicombe JH (ed). John Wiley & Sons, Toronto, pp. 245-266, 1996
16. Rest RF, **Speert DP**. Measurement of Nonopsonic Phagocytic Killing by Human Polymorphonuclear Neutrophils. In *Bacterial Pathogenesis*, Clark VL & Bavoil PM (ed.). Academic Press, pp. 475-483, 1997
17. **Speert DP**. Streptococcal Sore Throat, In *Therapeutic Choices*, 2nd Edition, J. Gray (Ed.-in-Chief), Canadian Pharmacists Association, Chap. 82, pp. 631-634, 1998
18. **Speert DP**, Heale J-P. Macrophages in bacterial infection. In *The Macrophage*, 2nd edition, Burke B and Lewis CE (ed.). Oxford University Press (in press)
19. Hancock REW, **Speert DP**. Antibiotic resistance in *Pseudomonas aeruginosa*: mechanism and impact on treatment. *Drug Resistance Updates* 3: 247-255, 2000
20. Davidson D, Currie A, **Speert DP**. *Pseudomonas aeruginosa* infections in individuals with cystic fibrosis: North American perspective. In *Severe Infections Caused by Pseudomonas aeruginosa*. Hauser A, (ed.) (in press) 2002

III. LETTERS AND EXTENDED ABSTRACTS

1. **Speert DP**, Wannamaker LW, Quie PG, 1980: Enhancement of phagocytosis of group A streptococci by oleic acid. *Current Chemotherapy and Infectious Diseases*. eds. Nelson JD and Grassi C. American Society for Microbiology, 803-804, (extended abstract).
2. **Speert DP**, Wannamaker LW, Quie PG: Surface hydrophobicity of Group A streptococci: Reply (Letter) *J Infect Dis*, 146: 577-578, 1982.
3. Murray AB, Laxer RM, Petty RE, **Speert DP**: Role of house dust mites in Kawasaki disease. *CMAJ*, 131: 720, 1984.
4. **Speert DP**, Davidson AGF, Wong LTK, Paranchych W: Communicability of *Pseudomonas* infections in patients with cystic fibrosis. *J Pediatr* 114: 1068-9, 1989.
5. **Speert DP**: Phenotypic conversion of *Pseudomonas aeruginosa*, Author's reply. *J Clin Microbiol* 29: 417, 1991.
6. **Speert DP**, Mahenthiralingam E, Barghouthi S: Regulation of Nonopsonic Phagocytosis of *Pseudomonas aeruginosa*. *Ped Pulmonol Suppl.* 8: 159-60, Sept. 1992
7. **Speert DP**, Ogle JW, LiPuma J: Cystic fibrosis camps. *Pediatr. Infect. Dis. J.* 12:789, 1993.
8. Mahenthiralingam E, Campbell ME, **Speert DP**: Transmissibility of *Burkholderia cepacia* in cystic fibrosis. *N Engl J Med* 332: 819, 1995
9. Mahenthiralingam E, Campbell ME, Henry DA, **Speert DP**: Molecular epidemiology of *Burkholderia cepacia* using random amplified polymorphic DNA (RAPD) analysis. *Ped Pulmonol Suppl.* 12:164-165, 1995
10. **Speert DP**: How drugs get to market. *Candid Facts*, Newsletter of Canadian CF Foundation, 4: 12-13, 1996
11. Davis HD, Langley JM, **Speert DP**. Publish or Perish – Reply, *CMAJ* 1997; 156:1383

IV. CONFERENCE PROCEEDINGS

1. **Speert DP**. 1991. *Pseudomonas cepacia* in Cystic Fibrosis. Canadian Cystic Fibrosis Foundation Workshop Report.